Market Cap 38.31M
Revenue (ttm) 650,000.00
Net Income (ttm) -51.79M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -7,967.69%
Debt to Equity Ratio 0.00
Volume 46,300
Avg Vol 349,208
Day's Range N/A - N/A
Shares Out 20.16M
Stochastic %K 16%
Beta N/A
Analysts Strong Sell
Price Target $15.25

Latest News on CAMP

CAMP4 to Participate in Upcoming Investor Conferences

Feb 6, 2025, 8:00 AM EST - 4 months ago

CAMP4 to Participate in Upcoming Investor Conferences


CAMP4 Reports Third Quarter 2024 Financial Results

Nov 21, 2024, 4:05 PM EST - 7 months ago

CAMP4 Reports Third Quarter 2024 Financial Results


CAMP4 Analyst Highlights Rare Disease Platform Potential

Nov 5, 2024, 3:06 PM EST - 7 months ago

CAMP4 Analyst Highlights Rare Disease Platform Potential


CAMP4 Announces Pricing of Initial Public Offering

Oct 10, 2024, 7:07 PM EDT - 8 months ago

CAMP4 Announces Pricing of Initial Public Offering


Camp4 Therapeutics Targets IPO On Early Positive Results

Oct 1, 2024, 4:30 PM EDT - 8 months ago

Camp4 Therapeutics Targets IPO On Early Positive Results


Kaiser Permanente-backed biopharma CAMP4 files for US IPO

Sep 20, 2024, 2:23 PM EDT - 9 months ago

Kaiser Permanente-backed biopharma CAMP4 files for US IPO


CAMP4 Therapeutics IPO Registration Document (S-1)

Sep 20, 2024, 1:35 PM EDT - 9 months ago

CAMP4 Therapeutics IPO Registration Document (S-1)